Loading…
Bicycle Therapeutics plc is projected to decline to $4.48 by 2027, a -2% move from its current price of $4.57. BCYC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $4.47 | $4.57 | $4.67 | -0.03% |
| May 30 | $4.43 | $4.57 | $4.71 | -0.05% |
| May 31 | $4.40 | $4.57 | $4.74 | -0.08% |
| Jun 1 | $4.38 | $4.57 | $4.76 | -0.10% |
| Jun 2 | $4.35 | $4.56 | $4.78 | -0.13% |
| Jun 3 | $4.33 | $4.56 | $4.80 | -0.15% |
| Jun 4 | $4.32 | $4.56 | $4.82 | -0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.32 | $4.56 | $4.82 | -0.18% |
| Week 2 | $4.21 | $4.55 | $4.93 | -0.36% |
| Week 3 | $4.13 | $4.55 | $5.00 | -0.54% |
| Week 4 | $4.06 | $4.54 | $5.07 | -0.72% |
| Week 5 | $4.00 | $4.53 | $5.13 | -0.90% |
| Week 6 | $3.95 | $4.52 | $5.18 | -1.08% |
| Week 7 | $3.90 | $4.51 | $5.23 | -1.26% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bicycle Therapeutics plc is a clinical-stage pharmaceutical company that develops a class of medicines for diseases underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline includes zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical.
Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
BCYC currently trades at $4.55 with a market capitalization of $317.64M and a rank of 3467. The stock’s current price and market position reflect a niche, clinical-stage biotechnology profile. Long-run forecasts describe a progression from neutral to bullish sentiment over time, with notable growth in the later years.
The near-term technical picture shows bearish sentiment, while the longer-term outlook moves toward bullish trajectories in the 2030s and beyond.
A major floor 17.5% below — a decisive break under it would weaken the trend.
The nearest floor, 4.8% below — buyers have tended to step in here.
The nearest ceiling, 16.6% above — a clean break opens room to run.
A major ceiling 58.0% above — clearing it would confirm fresh momentum.
Key BCYC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCYC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.51 | Buy | $4.53 | Buy |
| MA 10 | $4.51 | Buy | $4.56 | Buy |
| MA 20 | $4.67 | Sell | $4.64 | Sell |
| MA 50 | $4.76 | Sell | $4.88 | Sell |
| MA 100 | $5.37 | Sell | $5.36 | Sell |
| MA 200 | $6.34 | Sell | $6.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.35 | Neutral |
| Stoch RSI (14) | 70.26 | Neutral |
| CCI (20) | -41.46 | Neutral |
| Williams %R (14) | -59.26 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -4.99 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 40.74 | Neutral |
| TRIX (15) | -0.31 | Sell |
| Awesome (5,34) | -0.30 | Sell |
| Ultimate (7,14,28) | 51.62 | Neutral |
| Momentum (10) | -0.15 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 4.57 | Sell |
| ADX (14) | 15.21 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture shows bearish sentiment with an RSI of 40. The moving averages place price attention near the SMA50 of $4.78 and the SMA200 of $6.37. Support is indicated at $4.35 and resistance at $5.33. The 30-day price range spans $3.93 to $5.27, highlighting a relatively tight but range-bound setup in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.31 | $4.57 | $5.87 | 0% | Neutral | |
| $3.63 | $4.48 | $5.80 | -2% | Neutral | |
| $3.69 | $4.64 | $6.18 | +2% | Neutral | |
| $3.87 | $4.95 | $6.75 | +8% | Neutral | |
| $4.24 | $5.51 | $7.65 | +21% | Bullish | |
| $4.78 | $6.29 | $8.89 | +38% | Bullish | |
| $4.66 | $6.22 | $8.92 | +36% | Bullish | |
| $4.52 | $6.10 | $8.87 | +33% | Bullish | |
| $4.79 | $6.53 | $9.62 | +43% | Bullish | |
| $4.85 | $6.69 | $9.98 | +46% | Bullish | |
| $6.09 | $8.81 | $13.82 | +93% | Bullish | |
| $11.54 | $18.10 | $30.59 | +296% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $4.31 | $4.57 | $5.34 | +0.00% |
| June 2026 | $3.81 | $4.45 | $5.31 | -2.59% |
| July 2026 | $3.80 | $4.46 | $5.38 | +0.27% |
| August 2026 | $3.85 | $4.55 | $5.53 | +1.96% |
| September 2026 | $3.80 | $4.51 | $5.52 | -0.86% |
| October 2026 | $3.77 | $4.49 | $5.52 | -0.50% |
| November 2026 | $3.87 | $4.63 | $5.73 | +3.16% |
| December 2026 | $3.94 | $4.73 | $5.87 | +2.08% |
Click any year to see its month-by-month BCYC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BCYC price prediction for 2026 points to an average of $4.57 (low $4.31, high $5.87) — a potential gain of 0% on today's $4.57. Price action looks broadly range-bound.
In 2027, BCYC is projected to trade between $3.63 and $5.80, averaging $4.48 — a potential decline of -2% from today's $4.57. That is -2% versus the projected 2026 average. A consolidation phase looks the most probable path here.
Bicycle Therapeutics plc's 2028 outlook centres on $4.64, within a $3.69 to $6.18 range. That is up +4% on the projected 2027 average. That marks a +2% change versus current levels. Price action looks broadly range-bound.
By 2029, BCYC could reach as high as $6.75, with a base case around $4.95 and support toward $3.87 — roughly +8% from $4.57. A consolidation phase looks the most probable path here.
Expect BCYC to range from $4.24 to $7.65 through 2030. The $5.51 average target implies a +21% move from current prices. That is up +11% on the projected 2029 average. Momentum favours further upside here.
The BCYC price prediction for 2031 points to an average of $6.29 (low $4.78, high $8.89) — a potential gain of +38% on today's $4.57. Buyers look set to stay in control over this stretch.
In 2032, BCYC is projected to trade between $4.66 and $8.92, averaging $6.22 — a potential gain of +36% from today's $4.57. That is -1% versus the projected 2031 average. Momentum favours further upside here.
Bicycle Therapeutics plc's 2033 outlook centres on $6.10, within a $4.52 to $8.87 range. That is -2% versus the projected 2032 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, BCYC could reach as high as $9.62, with a base case around $6.53 and support toward $4.79 — roughly +43% from $4.57. Momentum favours further upside here.
Expect BCYC to range from $4.85 to $9.98 through 2035. The $6.69 average target implies a +46% move from current prices. That is up +2% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The BCYC price prediction for 2040 points to an average of $8.81 (low $6.09, high $13.82) — a potential gain of +93% on today's $4.57. Momentum favours further upside here.
In 2050, BCYC is projected to trade between $11.54 and $30.59, averaging $18.10 — a potential gain of +296% from today's $4.57. That is up +105% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BCYC today (≈ 218.818381 BCYC) could be worth
$3,959.55
+$2,959.55 (+296%) by 2050 · US Dollar
Based on the average projected BCYC price of $18.1 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCYCwould be worth at today's price.
$1,000 invested in BCYC on May 27, 2025 (≈ 124.533005 BCYC) would be worth
$569.12
-$430.88 (-43.1%) today · 0.57× · US Dollar
Based on a BCYC entry price of $8.03 vs. today's $4.57.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.42 | $1,033.94 | +3.4% |
| 1 month ago | $4.77 | $958.07 | -4.2% |
| 3 months ago | $5.64 | $810.28 | -19.0% |
| 6 months ago | $7.48 | $610.96 | -38.9% |
| 1 year ago | $8.03 | $569.12 | -43.1% |
| All time (5.0y) ago | $29.77 | $153.51 | -84.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCYC forecast.
Our base-case forecast reaches $9.10 around 2050.
Implied market cap at $9.10: $458.4M
The multi-year forecast begins with modest activity in 2026–2029, where the avg price sits around $4.55–$4.91 and ROIs range around 0 to 7.9. The outlook strengthens in 2030 with an avg price of $5.47 and a max of $7.67, accompanied by a 20.1 forecast ROI and bullish sentiment. From 2031 through 2035, the path remains bullish with rising averages and ROIs (e.g., 2031 avg $6.26, 2032 avg $6.14, 2033 avg $6.02, 2034 avg $6.50, 2035 avg $6.60).
The forecast accelerates toward 2040 with an avg price of $8.73 and a max of $13.92, yielding a 92 ROI and bullish sentiment. By 2050, the avg price is $17.86 with a max of $30.77 and a 292.5 ROI, continuing the bullish view while acknowledging the uncertainty and variability inherent in long-range projections.
Tap a question to reveal the answer.
2030 avg price $5.47 with a min of $4.17 and a max of $7.67; ROI 20.1; sentiment BULLISH.
Forecasts show a bullish view from 2030 onward, with earlier years (2026–2029) largely neutral and some years with modest negative or low ROIs (e.g., 2027 ROI -2.4). The near-term range and volatility are noted, with an annualized volatility of 40 and a bearish starting sentiment, so outcomes depend on execution and market factors.
Yes. The 2040 max price is $13.92, which exceeds $10, while the 2040 avg is $8.73. The forecast shows bullish momentum continuing into 2040 and beyond.
Current price is $4.55 and market cap is $317.64M.
2050 min $11.14, avg $17.86, max $30.77 with a roiPct of 292.5 and bullish sentiment.
Bicycle Therapeutics plc Community Discussion
0Share your Bicycle Therapeutics plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.